7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T63957 | PI3K-IN-29 | ||
PI3K-IN-29 是一种有效的 PI3K 抑制剂。PI3K-IN-29 对 U87MG、HeLa 和 HL60 细胞具有较好的抑制作用,IC50值分别为 0.264、2.04 和 1.14 µM。PI3K-IN-29 通过抑制PI3K 催化的Akt 的磷酸化来抑制PI3K/Akt 通路。 | |||
T62912 |
PI3K/HDAC-IN-2
|
||
PI3K/HDAC-IN-2 是一种有效的 PI3K/HDAC 双重抑制剂,能够作用于 PI3Kα (IC50: 226 nM)、PI3Kβ (IC50: 279 nM)、PI3Kγ (IC50: 467 nM)、PI3Kδ (IC50: 29 nM)、HDAC1 (IC50: 1.3 nM)、HDAC2 (IC50: 3.4 nM)、HDC4 (IC50: 973 nM)、HDAC6 (IC50: 17 nM)、HDAC8 (IC50: 12 nM)。PI3K/HDAC-IN-2 具有 PI3Kδ 和 I 类和 IIb 类 HDAC 选择性,并表现出显着的抗癌作用。 | |||
T79658 |
PI3Kδ-IN-14
|
PI3K | PI3K/Akt/mTOR signaling |
PI3Kδ-IN-14(化合物(S)-29)是一种高选择性PI3Kδ抑制剂,具有出色的靶点亲和力(IC50为0.8 nM,Kd为84.8 nM)。该化合物特异性结合至PI3Kδ激酶的ATP结合位点,并通过抑制PI3K/AKT信号通路发挥抗炎作用。此外,PI3Kδ-IN-14在改善急性肺损伤(ALI)方面显示出潜在效果。 | |||
T36314 |
Wortmannin-Rapamycin Conjugate
|
||
Phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) act synergistically in promoting cancer. Wortmannin is a potent inhibitor of PI3K enzymes, while rapamycin blocks mTOR Complex 1 TORC1. Wortmannin-rapamycin conjugate consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker. Hydrolysis of the prodrug linker in vivo releases the inhibitors. The wortmannin-rapamycin conjugate inhibits the growth of HT-29 colon tumors and A498 renal tumors in... | |||
T36085 |
PKI-179 hydrochloride
|
||
PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively), two common PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively), and mTOR (IC50 = 0.42 nM). PKI-179 is selective for PI3K and mTOR over a panel of 361 other kinases at IC50 values up to 50 μM, hERG (IC50 > 30 μM), and cytochrome P450 (CYP) isoforms (IC5... | |||
T72780 |
HSP90/mTOR-IN-1
|
||
HSP90/mTOR-IN-1 是一种有效的Hsp90和mTOR 抑制剂,IC50分别为 69 nM 和 29 nM。HSP90/mTOR-IN-1 通过过度激活PI3K/AKT/mTOR 通路抑制 SW780 细胞增殖。HSP90/mTOR-IN-1 通过对HSP90和mTOR 的选择性抑制来诱导细胞凋亡 (apoptosis) 和细胞自噬 (autophagy)。HSP90/mTOR-IN-1 在异种移植小鼠体内也表现出良好的抗肿瘤活性。HSP90/mTOR-IN-1 可用于膀胱癌的研究。 | |||
T36084 |
PKI-179
|
||
PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo[1][2]. PKI-179 inhibits the cell proliferation, with IC50s of 22 nM and 29 nM for MDA361 and PC3 cells, respectively[1].PKI-179 shows inhibitory activity against a panel of 361 other ... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN1405 |
Arnicolide D
山金车内酯 D,山金车内酯D |
Akt; Caspase; PI3K; STAT; mTOR | Apoptosis; Cytoskeletal Signaling; JAK/STAT signaling; PI3K/Akt/mTOR signaling; Proteases/Proteasome; Stem Cells |
Arnicolide D 是从石胡荽中分离出的一种倍半萜内酯,以浓度和时间依赖性方式抑制鼻咽癌细胞活力。它调节细胞周期,激活 caspase 信号通路并抑制 PI3K/AKT/mTOR 和 STAT3 信号通路。 |